Wednesday, August 15, 2018
 
 
Company News: Page (1) of 1 - 07/19/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
 
(July 19, 2018)

BEIJING, July 19, 2018 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia. The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country.

"The opening of these two divisions is an important milestone in company history," commented Zhang Yi, Founder and Chairman of Yisheng Biopharma. "Our product YivykaTM is approved in Cambodia for the treatment of advanced solid tumors, including lung, breast, liver, colorectal and stomach cancers. We are pleased to be in a position to expand access to the benefits that this product will bring to cancer patients and are grateful for the support we have received from the Ministry of Health of the Kingdom of Cambodia."

"ASEAN countries have witnessed a significant economic boom over the last decade and represent one of the fastest growing markets for the biopharmaceutical industry," added David Shao, Ph.D., President and CEO of Yisheng Biopharma. "With a population of over 600 million under-served individuals in these countries, we are committed to expanding and deepening our presence in this region of southeast Asia. We are conducting drug development in this region, with programs in immuno-oncology, rabies and hepatitis B infection, and are well positioned to introduce a series of innovative products into this region."



YivykaTM is an innovative immuno-oncology drug recently granted a drug registration license by the Ministry of Health of the Kingdom of Cambodia. YivykaTM is the first biological product introduced into the Cambodia market by Yisheng Biopharma. 

About Yisheng Biopharma Co., Ltd.

Yisheng Biopharma is a global biopharmaceutical company discovering, developing and commercializing innovative immunological biologics. With approximately 700 employees worldwide and operations in China, the United States, Singapore and certain Southeast Asian countries. 

www.yishengbio.com

 

Cision View original content:http://www.prnewswire.com/news-releases/yisheng-biopharma-announces-opening-of-new-business-divisions-in-cambodia-expanding-presence-within-southeast-asia-300683333.html

SOURCE Yisheng Biopharma Co., Ltd.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Science,Medical,Biology,Cancer,Business,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • New Report Identifies Unique Challenges for LGBT Community Facing Alzheimer's and Other Dementias
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease,
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease
  • Global Spinal Fusion Devices Market Expected to Reach USD 6.8 Billion By 2024: Zion Market Research

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • ViewRay Announces Pricing of Public Offering of Common Stock
  • Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players, financials and forecasts
  • CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
  • Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines